Human medicines European public assessment report (EPAR): Erbitux, cetuximab, Date of authorisation: 29/06/2004, ...
The most common side effects with Erbitux (seen in more than 1 patient in 10) are skin reactions such as rash, hypomagnesaemia (low blood magnesium levels), mild or moderate reactions linked to the infusion (such as fever, chills, dizziness and difficulty …